SCHEMBL1331820

SCHEMBL1331820

C=C(C[C@H](N)C(=O)O)C(N)=O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIK1 P39086 9/20 0.71
GRIK2 Q13002 6/20 0.71
GRM1 Q13255 1/20 0.71
GRM2 Q14416 1/20 0.71
SLC7A5 Q01650 1/20 0.44
ALOX15 P16050 1/20 0.43
BLM P54132 1/20 0.43
PMP22 Q01453 1/20 0.43
KMT2A Q03164 1/20 0.43
PTGS1 P23219 1/20 0.42
SLC7A11 Q9UPY5 1/20 0.42
GGT1 P19440 4/20 0.41
SLC1A1 P43005 3/20 0.41
GRIA4 P48058 3/20 0.41
GRIK3 Q13003 3/20 0.41
GRIK5 Q16478 3/20 0.41
SLC1A3 P43003 2/20 0.40
SLC1A2 P43004 2/20 0.40
GRIA2 P42262 2/20 0.39
GRIA1 P42261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1331822 1.00 GRIK1 (0.71) GRIK1GRIK2GRM1GRM2SLC7A5
SCHEMBL497587 0.83 GRIK1 (1.00) GRIK1GRIK2GRM1GRM2SLC7A5
SCHEMBL3981383 0.83 GRIK1 (1.00) GRIK1GRIK2GRM1GRM2SLC7A5
SCHEMBL1476505 0.83 GRIK1 (1.00) GRIK1GRIK2GRM1GRM2SLC7A5
Hydrochloric Acid SCHEMBL4186334 0.81 GRIK1 (0.95) GRIK1GRIK2GRM1GRM2SLC7A5
Hydrochloric Acid SCHEMBL6235798 0.81 GRIK1 (0.95) GRIK1GRIK2GRM1GRM2SLC7A5
Ammonia Solution, Strong SCHEMBL638403 0.81 GRIK1 (0.95) GRIK1GRIK2GRM1GRM2SLC7A5
SCHEMBL5797481 0.79 GRIK1 (0.68) GRIK1GRIK2GRM1GRM2SLC7A5
Aspartic Acid SCHEMBL8159324 0.77 GRIK1 (0.52) GRIK1GRIK2GRM1GRM2SLC7A5
Aspartic Acid SCHEMBL8159323 0.77 GRIK1 (0.52) GRIK1GRIK2GRM1GRM2SLC7A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122030393-A Plant salt-tolerant resistance inducer, screening method and application thereof 南通大学 2026-05-15 CN claimed
US-9101662-B2 Compositions with modulating agents FOAMIX PHARMACEUTICALS LTD. (IL) 2015-08-11 US claimed
US-8795693-B2 Compositions with modulating agents FOAMIX LTD. (IL) 2014-08-05 US claimed
CN-101611195-A Detoxifying pretreated lignocellulose-containing material NOVOZYMES NORTH AMERICA INC (US) 2009-12-23 CN claimed
EP-2097065-A2 FOAMABLE WATERLESS COMPOSITIONS WITH MODULATING AGENTS Foamix Ltd. (IL) 2009-09-09 EP claimed
EP-1554235-B1 PROCESS FOR SYNTHESIZING L-Y-METHYLENE GLUTAMIC ACID AND ANALOGS BIONUMERIK PHARMACEUTICALS INC (US) 2009-02-18 EP claimed
WO-2008152444-A2 FOAMABLE WATERLESS COMPOSITIONS WITH MODULATING AGENTS FOAMIX LTD. (US) 2008-12-18 WO claimed
US-20080206159-A1 Drug mixture contains solvents, nonionic surfactants, gelling agent, therapeutic active agent, liquefied or compressed gas propellant; pressurized dispenser; treating skin diseases, dermal and mucosal delivery; stable and non-irritating emulsions FOAMIX LTD. (IL) 2008-08-28 US claimed
EP-1373225-B1 PROCESS FOR COUPLING AMINO ACIDS TO AN ANTIFOLATE SCAFFOLD BIONUMERIK PHARMACEUTICALS INC (US) 2006-05-24 EP claimed
WO-2004021981-A2 METHODS FOR THE PREPARATION OF β-AMINO ACIDS WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2004-03-18 WO claimed
US-20030113882-A1 Methods for the preparation of beta-amino acids WISCONSIN ALUMNI RESEARCH FOUNDATION 2003-06-19 US claimed
EP-0731648-B1 FLAVOURING COMPOSITIONS AND METHOD FIRMENICH & CIE (CH) 2003-03-26 EP claimed
EP-0513068-B1 THREE NEW NON-POLYGLUTAMATABLE DEAZAAMINOPTERINS AND PROCESS FOR PREPARING THE SAME NAIR MADHAVAN G (US) 1995-09-13 EP claimed
CN-122030393-A Plant salt-tolerant resistance inducer, screening method and application thereof 南通大学 2026-05-15 CN disclosed
CN-122030393-A Plant salt-tolerant resistance inducer, screening method and application thereof 南通大学 2026-05-15 CN disclosed
CN-121380418-A SNP molecular marker related to cucumber and pseudomonas recruitment and application thereof 中国农业科学院蔬菜花卉研究所 2026-01-23 CN disclosed
EP-1205773-A2 Hydrogel contact lenses with improved biocompatibility Wöhlk-Contact-Linsen GmbH (DE) 2002-05-15 EP disclosed
EP-1185517-A1 ANTIBIOTIC PRODRUGS University of Massachusetts (US) 2002-03-13 EP disclosed
WO-2000071523-A1 ANTIBIOTIC PRODRUGS UNIVERSITY OF MASSACHUSETTS (US) 2000-11-30 WO disclosed
US-6031156-A NUCLEOTIDE SEQUENCES; FOR TRANSGENIC PLANTS WITH DARKNESS AND ORGAN SPECIFIC GENE EXPRESSION NEW YORK UNIVERSITY (US) 2000-02-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080206159-A1 Drug mixture contains solvents, nonionic surfactants, gelling agent, therapeutic active agent, liquefied or compressed gas propellant; pressurized dispenser; treating skin diseases, dermal and mucosal delivery; stable and non-irritating emulsions CUTA, SLTM, SMO GRIK1 2104/4885GRIK2 2050/4885GRM1 3005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.